Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Observational 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Breast Neoplasms 6Prostatic Neoplasms 5Neoplasms 5Multiple Myeloma 4Neoplasms, Plasma Cell 3Colorectal Neoplasms 3Hematologic Neoplasms 2Frailty 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Upper Excretory Tract Tumors 1Transfusion-Related Acute Lung Injury 1Thrombosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spondylitis, Ankylosing 1Sleep Initiation and Maintenance Disorders 1Sleep Disorders, Circadian Rhythm 1Sezary Syndrome 1Sarcopenia 1Sarcoglycanopathies 1Psoriasis 1Peripheral Arterial Disease 1Patient Acceptance of Health Care 1Ovarian Neoplasms 1Myocardial Infarction 1Myeloproliferative Disorders 1Mycoses 1Melanoma 1Malnutrition 1

Interventions

Immunoenzyme Techniques 5Flow Cytometry 4Standard of Care 3Psychiatric Rehabilitation 3Surveys and Questionnaires 2Reverse Transcriptase Polymerase Chain Reaction 2Polymerase Chain Reaction 2Microarray Analysis 2Interviews as Topic 2Immunologic Techniques 2Gene Expression Profiling 2Amplified Fragment Length Polymorphism Analysis 2plerixafor 1Watchful Waiting 1Urination 1Platelet Aggregation 1Piperacillin, Tazobactam Drug Combination 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Lenalidomide 1Influenza Vaccines 1In Situ Hybridization, Fluorescence 1Immunosuppression Therapy 1Glycopeptides 1Focus Groups 1Fentanyl 1Enzyme-Linked Immunosorbent Assay 1Enteral Nutrition 1Electrophoresis, Polyacrylamide Gel 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Neoplasms, Plasma Cell × Standard of Care × Clear all
NCT06504524 2025-06-27

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Pfizer

Completed
633 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05932290 2024-10-29

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Pfizer

Completed
514 enrolled 16 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05565391 2024-05-21

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Pfizer

Completed
508 enrolled 16 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡